Rilzabrutinib
- Generic Name
- Rilzabrutinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C36H40FN9O3
- CAS Number
- 1575591-66-0
- Unique Ingredient Identifier
- 5G1WE425BI
- Background
Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated for the treatment of immune disorders, such as immune thrombocytopenic purpura.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT06500702
- Locations
- 🇺🇸
Investigational Site Number : 8400005, El Paso, Texas, United States
A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)
- Conditions
- Interventions
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Principia Biopharma, a Sanofi Company
- Target Recruit Count
- 29
- Registration Number
- NCT06444204
- Locations
- 🇺🇸
Investigational Site Number: 0001, Orlando, Florida, United States
🇺🇸Investigational Site Number: 0002, Miami, Florida, United States
Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Principia Biopharma, a Sanofi Company
- Target Recruit Count
- 23
- Registration Number
- NCT06444191
- Locations
- 🇺🇸
Investigational Site Number: 0001, Glendale, California, United States
Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine
- Conditions
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 161
- Registration Number
- NCT05107115
- Locations
- 🇪🇸
Investigational Site Number :7240007, Pozuelo de Alarcón, Madrid, Spain
🇪🇸Investigational Site Number : 7240006, Pamplona, Navarra, Spain
🇪🇸Investigational Site Number :7240006, Pamplona, Navarra, Spain
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 196
- Registration Number
- NCT05104892
- Locations
- 🇪🇸
Investigational Site Number : 7240004, Santander, Cantabria, Spain
🇧🇬Investigational Site Number : 1000004, Kozloduy, Bulgaria
🇧🇬Investigational Site Number : 1000003, Sevlievo, Bulgaria
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 124
- Registration Number
- NCT05018806
- Locations
- 🇺🇸
Integrative Skin Care of MS/SKYCRNG Site Number : 8400011, Ridgeland, Mississippi, United States
🇵🇱Investigational Site Number : 6160005, Gdansk, Pomorskie, Poland
🇵🇱Investigational Site Number : 6160002, Lodz, Poland
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 22
- Registration Number
- NCT05002777
- Locations
- 🇺🇸
University of Southern California_Investigational Site Number: 8400009, Los Angeles, California, United States
🇺🇸TOI Clinical Research LLC_Santa Ana_Investigational Site Number: 8400006, Santa Ana, California, United States
🇺🇸The Lundquist Institute_Investigational Site Number: 8400005, Torrance, California, United States
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
- Conditions
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Principia Biopharma, a Sanofi Company
- Target Recruit Count
- 194
- Registration Number
- NCT04562766
- Locations
- 🇺🇸
University of Southern California_Investigational Site Number 84024, Los Angeles, California, United States
🇺🇸UCSF Benioff Children's Hospital San Francisco_Investigational Site Number 84020, San Francisco, California, United States
🇺🇸Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center_Investigational Site Number 84037, Torrance, California, United States
Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Principia Biopharma, a Sanofi Company
- Target Recruit Count
- 27
- Registration Number
- NCT04520451
- Locations
- 🇺🇸
Investigational Site Number 84016, Boston, Massachusetts, United States
🇫🇷Investigational Site Number 25013, Marseille, France
🇺🇸Investigational Site Number 84019, Stanford, California, United States
A Study of PRN1008 in Patients With Pemphigus
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Principia Biopharma, a Sanofi Company
- Target Recruit Count
- 131
- Registration Number
- NCT03762265
- Locations
- 🇬🇧
Central Recruiting (Principia Biopharma), London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.